 |
1 Disease |  |
4 Trials |
|
4 Trials |  |
162 News |  |
| 12» |
- EFFICACY AND SAFETY OF FGFR INHIBITORS IN CHOLANGIOCARCINOMA, A SYSTEMATIC REVIEW AND META ANALYSIS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2655;
FGFR inhibitors present a promising targeted approach adding to the arsenal of drugs available for the treatment of cholangiocarcinoma. Continued research efforts and Phase 3 trial data are crucial to understand the efficacy, outcomes and safety profile of these novel drugs.
- Cyramza (ramucirumab) / Eli Lilly, derazantinib (ARQ 087) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Phase classification, Combination therapy, Monotherapy: FIDES-03: Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=47, Terminated, Sponsor: Basilea Pharmaceutica
Continued research efforts and Phase 3 trial data are crucial to understand the efficacy, outcomes and safety profile of these novel drugs. Phase classification: P1b/2 --> P1/2
- The role of tumor molecular profiling in patients with advanced biliary tract cancer receiving systemic treatment (ePoster Area) - Dec 26, 2023 - Abstract #LCS2024LCS_203;
mOS was numerically longer in pts receiving targeted therapy, and in those with IDH1 mutated or FGFR2 rearranged tumors, but failed to reach statistical significance, probably due to the small sample size. Larger studies could provide additional information regarding the prognostic and predictive value of pivotal molecular alterations in BTC.
- | derazantinib (ARQ 087) / Merck (MSD)
Journal: Derazantinib Inhibits the Bioactivity of Keloid Fibroblasts via FGFR Signaling. (Pubmed Central) - Dec 23, 2023
Also, derazantinib inhibited the expression of FGFR1 and PAI-1 and reduced the weight of the implanted keloid from the xenograft mice model. These findings suggest that derazantinib may be a potent therapy for keloids via FGFR signaling.
- |||||| derazantinib (ARQ 087) / Merck (MSD)
Metastases: Results from the phase 1b/2 #FIDES02 study: Derazantinib for metastatic #BladderCancer with activating FGFR1/2/3 genetic aberrations. @AndreaNecchi @SanRaffaeleMI joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/7XkvtuwvBN (Twitter) - Jul 27, 2023
- |||| Clinical: Exciting developments in urothelial cancer treatment! Enfortumab vedotin, sacituzumab govitecan, and derazantinib are showing promise. Looking forward to EV and pembrolizumab results in first-line and MIBC. SG vs. chemo in platinum refractory disease is generating buzz.… https://t.co/XrJPm7T3jG (Twitter) - Jul 18, 2023
- |||||| derazantinib (ARQ 087) / Merck (MSD)
Metastases: Results from the phase 1b/2 #FIDES02 study: Derazantinib for metastatic #BladderCancer with activating FGFR1/2/3 genetic aberrations. @AndreaNecchi @SanRaffaeleMI joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/7XkvtuwvBN (Twitter) - May 30, 2023
- || derazantinib (ARQ 087) / Merck (MSD)
PK/PD data, Preclinical, Journal: Lack of pharmacokinetic interaction between derazantinib and naringin in rats. (Pubmed Central) - Mar 14, 2023
Co-administration of naringin with derazantinib was not associated with significant changes in pharmacokinetic parameters. Thus, this study suggests that the combination of derazantinib with naringin can safely be administered concomitantly without dose adjustment.
- | derazantinib (ARQ 087) / Merck (MSD), paclitaxel / Generic mfg.
Preclinical, Journal: The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo. (Pubmed Central) - Mar 13, 2023
The combination showed synergy (5) or additivity (2), and no antagonism, with synergy significantly associated (P < 0.05) with higher levels of M2-type macrophages. The association of strong efficacy of the combination in vivo with M2 macrophages, which are known to express CSF1R, and the absence of synergy in vitro is consistent with the tumor microenvironment also being a factor in DZB efficacy and suggests additional means by which DZB could be stratified for cancer treatment in the clinic.
- ||| Cyramza (ramucirumab) / Eli Lilly, derazantinib (ARQ 087) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Trial termination, Combination therapy, Monotherapy: FIDES-03: Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (clinicaltrials.gov) - Feb 16, 2023
P1b/2, N=47, Terminated, Sponsor: Basilea Pharmaceutica
The association of strong efficacy of the combination in vivo with M2 macrophages, which are known to express CSF1R, and the absence of synergy in vitro is consistent with the tumor microenvironment also being a factor in DZB efficacy and suggests additional means by which DZB could be stratified for cancer treatment in the clinic. Completed --> Terminated; Terminated prematurely for administrative reasons not related to patient safety.
- | derazantinib (ARQ 087) / Merck (MSD)
Preclinical, Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Tumor cell: Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models. (Pubmed Central) - Feb 3, 2023
Similar modulation of the tumor microenvironment was observed in an FGFR-insensitive syngeneic bladder model, MBT-2. These data confirm CSF1R as an important oncology target for DZB and provide mechanistic insight for the ongoing clinical trials, in which DZB is combined with the PD-L1 antibody, atezolizumab.
- || Cyramza (ramucirumab) / Eli Lilly, derazantinib (ARQ 087) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: FIDES-03: Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (clinicaltrials.gov) - Jan 17, 2023
P1b/2, N=47, Completed, Sponsor: Basilea Pharmaceutica
These data confirm CSF1R as an important oncology target for DZB and provide mechanistic insight for the ongoing clinical trials, in which DZB is combined with the PD-L1 antibody, atezolizumab. Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> Dec 2022 | Trial primary completion date: Jul 2023 --> Dec 2022
- derazantinib (ARQ 087) / Merck (MSD)
Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study. (On Demand | Level 1, West Hall; Poster Board No. K5) - Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_518;
P1b/2, P2
Derazantinib showed a well-manageable safety profile with low rates of hand-foot syndrome, stomatitis, nail toxicity and retinal side effects. Clinical trial information: NCT04045613.
- derazantinib (ARQ 087) / Merck (MSD)
Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study (Pink Area, Coral 3) - Dec 27, 2022 - Abstract #EAU2023EAU_1541;
P1b/2, P2
- ||| derazantinib (ARQ 087) / Merck (MSD)
Trial completion, Metastases: FIDES-01: Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Nov 23, 2022
P2, N=148, Completed, Sponsor: Basilea Pharmaceutica
Clinical trial information: NCT04045613. Active, not recruiting --> Completed
- ||| derazantinib (ARQ 087) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Trial completion, Trial completion date, Trial primary completion date: FIDES-02: Derazantinib and Atezolizumab in Patients With Urothelial Cancer (clinicaltrials.gov) - Oct 20, 2022
P1b/2, N=95, Completed, Sponsor: Basilea Pharmaceutica
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Sep 2022 | Trial primary completion date: Jul 2023 --> Sep 2022
- ||| derazantinib (ARQ 087) / Merck (MSD)
Clinical: Derazantinib Demonstrates Promising Efficacy in Intrahepatic Cholangiocarcinoma @myESMO #ESMO2022 #blcsm #oncology https://t.co/TOyHlIwpnC (Twitter) - Oct 5, 2022
- derazantinib (ARQ 087) / Merck (MSD)
Derazantinib, an inhibitor of fibroblast growth factor receptors 1-3, increases the efficacy of paclitaxel combined with a VEGFR2-antibody in murine syngeneic tumor models (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_294;
P1b/2
These data support the ongoing clinical trial with DZB in GC (FIDES-03, NCT04604132). No
- ||| Cyramza (ramucirumab) / Eli Lilly, derazantinib (ARQ 087) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Enrollment closed, Enrollment change, Combination therapy, Monotherapy: FIDES-03: Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (clinicaltrials.gov) - Aug 9, 2022
P1b/2, N=47, Active, not recruiting, Sponsor: Basilea Pharmaceutica
No Recruiting --> Active, not recruiting | N=254 --> 47
- ||| derazantinib (ARQ 087) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Enrollment closed, Enrollment change: FIDES-02: Derazantinib and Atezolizumab in Patients With Urothelial Cancer (clinicaltrials.gov) - Aug 9, 2022
P1b/2, N=95, Active, not recruiting, Sponsor: Basilea Pharmaceutica
Recruiting --> Active, not recruiting | N=254 --> 47 Recruiting --> Active, not recruiting | N=272 --> 95
- ||| rogaratinib (BAY 1163877) / Bayer, derazantinib (ARQ 087) / Merck (MSD)
Ma'am, Derazantinib compassionate access program is available for Cholangiocarcinoma and Rogaratinib (Beyer) compassionate access is available for multiple primaries and FGFR1 also. (Twitter) - Jul 30, 2022
- derazantinib (ARQ 087) / Merck (MSD)
Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2485;
P2
Conclusions Derazantinib results in meaningful clinical benefit for pts with FGFR2 genetic aberrations including FGFR2 F and FGFR2 MA . Derazantinib-related toxicities were limited: PPE, stomatitis, retinal or nail toxicity were infrequent in the study population.
- || derazantinib (ARQ 087) / Merck (MSD)
Enrollment closed, Metastases: FIDES-01: Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Jun 14, 2022
P2, N=148, Active, not recruiting, Sponsor: Basilea Pharmaceutica
Derazantinib-related toxicities were limited: PPE, stomatitis, retinal or nail toxicity were infrequent in the study population. Recruiting --> Active, not recruiting
- ||||| derazantinib (ARQ 087) / Basilea, Tecentriq (atezolizumab) / Roche
ADVANCE trial in FGFR2+ #cholangiocarcinoma #NCT05174650 Evaluation combination of: ✅#Derazantinib ➡️FGFRi: targeting tumor cells ➡️CSF1R: targeting immunosuppressive myeloid cells doi:10.1136/gutjnl-2021-326514 ✅#Atezolizumab ➡️PD-L1: unleashing T cells #PrecisionMedicine (Twitter) - Jun 12, 2022
P2
- |||||| derazantinib (ARQ 087) / Basilea, Tecentriq (atezolizumab) / Roche
Clinical: IKF is happy to announce that the ADVACE study has recruited its first patient. The IIT led by Prof. Arndt Vogel evaluates an innovative combination of Atezolizumab and Derazantinib for pts with bile duct cancer and FGFR fusions/rearmaments (Twitter) - Apr 25, 2022
- | derazantinib (ARQ 087) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Enrollment open, Trial initiation date, Metastases: Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements (clinicaltrials.gov) - Apr 6, 2022
P2, N=37, Recruiting, Sponsor: Institut f
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2022 --> Apr 2022
- derazantinib (ARQ 087) / Basilea
Derazantinib, an FGFR1-3 inhibitor, inhibits CSF1R in macrophages and tumor cell lines, and synergizes with a PDL1-antibody in an FGFR-driven murine syngeneic model (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_6960;
P1b/2
In combination with a murine PDL1-Ab, DZB showed a positive interaction in the orthotopic syngeneic breast tumor model, 4T1, against both the primary tumor and metastases. These data support clinical trials in which DZB is combined with the PDL1-Ab, atezolizumab (NCT04604132, NCT04045613).
- Clinical outcomes and genomic evolution of FGFR2 fusions/rearrangements in intrahepatic cholangiocarcinoma (Section 34) - Mar 9, 2022 - Abstract #AACR2022AACR_5208;
The genomic evolution post-progression on FGFR inhibition involves acquired resistance in multiple pathways. Targeting co-alterations acquired post-progression with drug combination may overcome these resistance mechanisms and potentiate the efficacy of FGFR inhibition.
- | derazantinib (ARQ 087) / Basilea
Journal: Derazantinib: an investigational drug for the treatment of cholangiocarcinoma. (Pubmed Central) - Jan 11, 2022
The clinical safety profile of derazantinib was well manageable and compared favorably to the FGFR inhibitor class, particularly with a low incidence of drug-related hand-foot syndrome, stomatitis, retinal and nail toxicity. These findings support the need for increased molecular profiling of cholangiocarcinoma patients.
- | derazantinib (ARQ 087) / Merck (MSD), Tecentriq (atezolizumab) / Roche
New P2 trial, Metastases: Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements (clinicaltrials.gov) - Jan 2, 2022
P2, N=37, Not yet recruiting, Sponsor: Institut f
- derazantinib (ARQ 087) / Basilea
Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01. (In-Person Only | Level 1, West Hall; Poster Board - M9) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_280;
P2
To our knowledge, this is the first report of clinically meaningful anti-tumor efficacy in a prospectively planned cohort of iCCA pts harboring FGFR2M/A. The study is ongoing to accrue 43 patients, assessing derazantinib as a therapeutic option for FGFR2M/A+ iCCA pts after disease progression on first-line treatment.
- derazantinib (ARQ 087) / Basilea
[VIRTUAL] Derazantinib, an inhibitor of fibroblast growth factor receptors 1-3, synergises with paclitaxel in pre-clinical gastric tumor models () - Sep 30, 2021 - Abstract #AACRNCIEORTC2021AACR_NCI_EORTC_414;
- || derazantinib (ARQ 087) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: FIDES-01: Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Aug 18, 2021
P2, N=143, Recruiting, Sponsor: Basilea Pharmaceutica
The study is ongoing to accrue 43 patients, assessing derazantinib as a therapeutic option for FGFR2M/A+ iCCA pts after disease progression on first-line treatment. Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Oct 2021 --> Jun 2022
- derazantinib (ARQ 087) / Basilea
[VIRTUAL] Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01 () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1450;
P2
Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Oct 2021 --> Jun 2022 Derazantinib showed clinically meaningful efficacy with durable objective responses, and a manageable safety profile with a particularly low incidence of drug-related hand-foot syndrome, stomatitis, retinal or nail toxicity in pts with iCCA harboring FGFR2fus.
- || derazantinib (ARQ 087) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date: FIDES-02: Derazantinib and Atezolizumab in Patients With Urothelial Cancer (clinicaltrials.gov) - Jul 21, 2021
P1b/2, N=272, Recruiting, Sponsor: Basilea Pharmaceutica
Derazantinib showed clinically meaningful efficacy with durable objective responses, and a manageable safety profile with a particularly low incidence of drug-related hand-foot syndrome, stomatitis, retinal or nail toxicity in pts with iCCA harboring FGFR2fus. Trial completion date: May 2022 --> Oct 2023 | Trial primary completion date: Apr 2022 --> Jul 2023
- || Clinical, Review, Journal: FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. (Pubmed Central) - Jul 4, 2021
Along with these agents, many phase II/III clinical trials are currently evaluating the use of derazantinib, infigratinib, and futibatinib either alone or in combination with immunotherapy...In addition, we proposed treatment guidelines for the management of FGFR-inhibitor-associated toxicities. This work would invariably help practicing oncologists to effectively manage the unique toxicities of FGFR inhibitors.
- ||| Journal, Adverse events: Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, And Management Guidelines. (Pubmed Central) - Jun 22, 2021
We reviewed skin AEs reported with FGFR inhibitors and provide management and supportive care guidelines for physicians, aiming to increase awareness of skin events in clinical practice and provide practical guidance on the most effective treatment strategies. Early intervention and effective management may improve treatment adherence, optimize outcomes, and improve patient quality of life.
- | Journal, IO biomarker: Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: Leading the way for precision medicine in biliary tract cancer [BTC]? (Pubmed Central) - May 13, 2021
Infigratinib, futibatinib, pemigatinib and derazantinib have all demonstrated promising activity in patients with cholangiocarcinoma harboring FGFR2 fusion. Eventually, head-to-head trials will be needed to fully understand the benefits of each agent and the role of reversible versus irreversible FGFR2 inhibitors.
- || Clinical, Review, Journal: Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations. (Pubmed Central) - May 1, 2021
We review the FGFR pathway and discuss emerging issues including resistance to FGFR inhibitors. We end with a discussion on future considerations to optimize the potential of this class of therapeutics in advanced cholangiocarcinoma.
- Padcev (enfortumab vedotin) / Seagen, Astellas
[VIRTUAL] Patient outcomes following disease progression with enfortumab-vedotin (EV) in metastatic urothelial carcinoma (mUC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4445;
Patients who did receive treatment had significantly increased OS . There is a clear gap in literature and evidence-based guidance for treatment following EV progression and further studies are required with larger samples accounting for confounding factors to further evaluate best practise post disease progression on EV.
- ||||| derazantinib (ARQ 087) / Basilea
Have tried non-selective inhinibitors of FGFR with some success . Basilea have approved derazantinib on compassionate grounds . Can share details if you need . (Twitter) - Mar 23, 2021
- JQ-1 / Roche, molibresib (GSK525762) / GSK, Balversa (erdafitinib) / J&J, Otsuka
[VIRTUAL] Altered response to BET-bromodomain inhibitors JQ1 and I-BET-762 targeting c-Myc in erdafitinib-resistant endometrial carcinoma cell line AN3 CA () - Mar 11, 2021 - Abstract #AACR2021AACR_3684;
In conclusion, we show that multiple factors contribute to the development of resistance against erdafitinib in an FGFR2-mutant endometrial carcinoma cell line. BET-bromodomain inhibitors are of potential interest as therapeutic agents to overcome resistance against FGFR inhibitors.
- ||| derazantinib (ARQ 087) / Basilea, Pemazyre (pemigatinib) / Incyte
Dear #PrecisionMedicine community, We have a pat w FGFR3-TACC3 fusion & CNS mets 🧠 Anyone aware of data on CNS activity of Pemigatinib or Derazantinib? @OncoAlert 🚨 @VivekSubbiah @Dr_R_Kurzrock @pashtoonkasi @jacobadashek @DocCatenacci @MPishvaian @rdienstmann @alexdrilon (Twitter) - Mar 4, 2021
- derazantinib (ARQ 087) / Basilea, Tecentriq (atezolizumab) / Roche
[VIRTUAL] Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: Results from the dose-finding phase Ib substudy of FIDES-02. () - Jan 8, 2021 - Abstract #ASCOGU2021ASCO_GU_580;
P1b/2
DZB can be safely dosed at its monotherapy RP2D in this novel combination with AZB. The anti-tumor efficacy of DZB+AZB is currently being investigated in adequately designed cohorts of FIDES-02 with enrichment for UC pts with FGFR GA.
- | derazantinib (ARQ 087) / Basilea
Journal: Probing the Effects of the FGFR-Inhibitor Derazantinib on Vascular Development in Zebrafish Embryos. (Pubmed Central) - Jan 6, 2021
For this purpose, we used the developing vasculature in the zebrafish embryo as a model system for angiogenesis in vivo. We show that DZB interferes with multiple angiogenic processes that are linked to FGF and VEGF signalling, revealing a potential dual role for DZB as a potent anti-angiogenic treatment.
- derazantinib (ARQ 087) / Basilea
[VIRTUAL] Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in pre-clinical models () - Sep 7, 2020 - Abstract #AACRNCIEORTC2020AACR_NCI_EORTC_138;
Background: Derazantinib (DZB) is a fibroblast growth factor receptor inhibitor (FGFRi) with clinical activity in FGFR2-fusion intrahepatic cholangiocarcinoma. The effects of DZB on HUVEC proliferation, EB permeability, R2* and fBV are consistent with an anti-angiogenic component to the compound’s mechanism of action that may facilitate clinical activity against some solid tumors.
- derazantinib (ARQ 087) / Basilea
[VIRTUAL] Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in pre-clinical models () - Sep 7, 2020 - Abstract #AACRNCIEORTC2020AACR_NCI_EORTC_137;
Background: Derazantinib (DZB) is a fibroblast growth factor receptor inhibitor (FGFRi) with clinical activity in FGFR2-fusion intrahepatic cholangiocarcinoma. The effects of DZB on HUVEC proliferation, EB permeability, R2* and fBV are consistent with an anti-angiogenic component to the compound’s mechanism of action that may facilitate clinical activity against some solid tumors.
- || derazantinib (ARQ 087) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: FIDES-01: Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Aug 17, 2020
P2, N=143, Recruiting, Sponsor: Basilea Pharmaceutica
The effects of DZB on HUVEC proliferation, EB permeability, R2* and fBV are consistent with an anti-angiogenic component to the compound’s mechanism of action that may facilitate clinical activity against some solid tumors. Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Oct 2021
- derazantinib (ARQ 087) / Basilea
[VIRTUAL] Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR-inhibitors derazantinib and erdafitinib: An analysis in safety relevant normal tissues from urothelial cancer (UC) patient-derived mouse xenograft (PDX) models (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2689;
P1b/2
Legal entity responsible for the study: Basilea Pharmaceutica International Ltd. Funding: Basilea Pharmaceutica International Ltd.
- derazantinib (ARQ 087) / Basilea
[VIRTUAL] Derazantinib (DZB), an oral fibroblast growth factor receptor inhibitor (FGFRi), shows promising activity in PDX-tumour models with aberrations in FGFR1-3 (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_822;
Legal entity responsible for the study: Basilea Pharmaceutica Limited. Funding: Basilea Pharmaceutica AG.